Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trialsMassimo Gentile, Pellegrino Musto, Roberta Della Pepa et al.|Haematologica|2023Cited by 19
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximabMassimo Gentile, Fortunato Morabito, Tait D. Shanafelt et al.|Leukemia|2018Cited by 9
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trialsEnrica Antonia Martino, Pellegrino Musto, Salvatore Palmieri et al.|Hematological Oncology|2024Cited by 7